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The accuracy of antimicrobial susceptibility tests is a crucial step for the clinical management
of patients with serious infections. They must be reliable and precise because they will guide
antimicrobial therapy. Our main objective was to compare the results of susceptibility testing
performed by the SENTRY coordinator laboratory with those reported by the participating Latin
American medical centers. A total of 10,277 bacterial isolates were tested by the reference broth
microdilution method at the coordinator laboratory in the United States. The tests were performed
and interpreted following the National Committee for Clinical Laboratory Standards (NCCLS)
recommendations. Ten antimicrobial agent-organism combinations were analyzed. The
susceptibility methods utilized in each of the medical centers were also evaluated. Total agreement
of the results was obtained in nearly 88% of the antimicrobial agent-organism combinations. “Very
major” (false-susceptible results) and “major errors” (false-resistant results) were observed in
12% and 6% of the cases, respectively. The highest disagreements were observed for coagulase-
negative Staphylococcus – oxacillin (20% - very major error) and Burkholderia cepacia – imipenem
(21% – very major error). The susceptibility method with the highest agreement rate was Etest
(92%) > PASCO (91%) > agar dilution (91%) > MicroScan (90%) > Vitek (87%). External
quality assurance data obtained by surveillance programs such as the SENTRY Antimicrobial
Surveillance Program are not only helpful for detecting the emergence of patterns of antimicrobial
resistance, but also to monitor the performance of the participating microbiology laboratories.
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The clinical microbiology laboratory plays an
important role in antibiotic selection and in the
performance of routine antimicrobial susceptibility
testing of clinical isolates [1]. Antimicrobial resistance
has emerged in bacterial pathogens throughout the
world [2], and the Enterobacteriaceae, Pseudomonas
spp., Staphylococcus spp. and Enterococcus spp. are
just a few examples of the bacteria involved in the rising
problem of resistance detected by both national and
international surveillance programs during the past few
years [3-6]. For this reason, antimicrobial susceptibility
testing has become an essential component in guiding
antimicrobial therapy.
Nosocomial infections are the main cause of
morbidity and mortality in the Unites States.
Hospitalized patients are more susceptible to infections
because of their underlying disease conditions, in
addition to exposure during invasive procedures [7].
Microorganisms isolated from these patients may be
resistant, and it can be difficult to detect emerging
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antimicrobial resistance patterns and to ensure the
efficiency of reporting strategies for antimicrobial
resistance. Failure of a test to predict antimicrobial
resistance can result in increased morbidity or mortality.
A wide variety of antimicrobial susceptibility systems
are available to clinical microbiology laboratories. They
must be reliable and precise, because their results will
guide antimicrobial therapy. The main objective of our
study was to compare the susceptibility testing results
of the reference methodology performed by the
SENTRY coordinator laboratory with those reported
by the Latin American participating medical centers in
order to assess the accuracy of the data submitted by
the participating laboratories.
Materials and Methods
Study design. The SENTRY Antimicrobial Surveillance
Program was established to monitor the prominent
pathogens and antimicrobial resistance patterns of
nosocomial and community-acquired infections via a
broad network of sentinel hospitals distributed by
geographic location and size. The monitored infections
include blood stream infections (BSI), outpatient
respiratory infections, lower respiratory tract infections
in hospitalized patients (LRTI), skin and soft tissue
infections in hospitalized patients (SSTI), and urinary
tract infections in hospitalized patients (UTI). The
participating laboratories were distributed throughout
seven countries, including Brazil (São Paulo, Rio de
Janeiro, Porto Alegre and Florianopolis), Argentina
(Buenos Aires and San Isidro), Chile (Santiago, two
centers), Colombia (Medellin), Mexico (Mexico City,
three centers) and Uruguay (Montevideo). In 1998,
the center located in Montevideo was replaced by a
Venezuelan center located in Caracas.
Each participating center contributed results
(organism identification, date of isolation, antimicrobial
susceptibility profile, etc) for the first 20 consecutive
episodes of BSI per month, 100 consecutive episodes
of LRTI per year, 50 consecutive isolates from SSTI
per year, and 50 consecutive isolates from UTI per year.
Only one isolate per patient was included in the study
and all isolates were saved on agar slants and sent to
the coordinating laboratory (RN Jones, Iowa, USA)
for storage and further characterization by reference
identification and susceptibility testing methods. All
isolates recovered and data collected from January
1997 to December 2000 were evaluated.
Species identification. All isolates were identified at
the participating institution by the routine methodology
in use in each laboratory. On receipt at the University of
Iowa, isolates were subcultured on blood agar to ensure
viability and purity. Species identifications were
confirmed or performed with the use of the Vitek
system (bioMérieux Vitek) or API (bioMérieux
Vitek) products, along with standard reference
methods. Isolates were frozen at -70°C until they were
processed.
Susceptibility testing. Antimicrobial susceptibility
testing of isolates was performed at the reference
laboratory by reference broth microdilution methods
as described by the National Committee for Clinical
Laboratory Standard (NCCLS) [8]. Microdilution
trays were purchased from MicroScan, TREK, and
PML Microbiologicals. Antimicrobial agents were
obtained from their respective manufacturers.
Quality control. Quality control was performed at the
coordinator laboratory by testing E. coli American Type
Culture Collection (ATCC) 25922, Staphylococcus
aureus ATCC 29213, Pseudomonas aeruginosa
ATCC 27853, Streptococcus pneumoniae ATCC
49619, and Enterococcus faecalis ATCC 29212.
Interpretive criteria for each antimicrobial tested were
those published by the NCCLS.
Categorical agreement. Broth microdilution
performed at the coordinating laboratory was
considered the reference method (gold standard). Broth
microdilution results were compared to the antimicrobial
susceptibility results submitted by the participating
medical laboratories using the local routine tests,
including: disk diffusion, agar-dilution, MicroScan,
Vitek, Pasco and Etest. Categorical agreement
was considered when the test result provided by the
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participating laboratory and the result of the reference
laboratory was in the same susceptibility category.
Susceptibility categories were determined according
to the NCCLS breakpoint recommendations [8]. A
previous NCCLS document [9] was used for
coagulase-negative Staphylococcus isolates in 1997
and 1998, since the oxacillin breakpoint for this
microorganism had changed in 1999.
Errors were determined by previously published
methods. “Very major” errors indicate false-susceptible
results and they were calculated by dividing the number
of false-susceptible results reported by the participating
centers by the number of true resistant strains found by
the reference laboratory. “Major” errors indicate false-
resistant results and they were calculated by dividing the
number of false-resistant results reported by the
participating centers by the number of true resistant strains
based found by the reference laboratory. Rates of
category agreement < 10.0%, very major < 1.5% and
major error < 5.0% were considered acceptable [10].
Ten antimicrobial agent-organism combinations
were studied for all sites: Staphylococcus aureus–
oxacillin; coagulase-negative Staphylococcus
(CoNS)–oxacillin; Klebsiella spp.–ceftriaxone;




aeruginosa–imipenem. The antimicrobial agent-
organism CoNS–oxacillin analysis combinations were
divided into two different steps since the oxacillin
breakpoint had been modified during the study interval.
SPSS for Windows Release 10.0.5 Standard Version
was used to perform statistical analyses.
Results
The antimicrobial susceptibility testing methods used
by the participating medical centers, and the respective
number of isolates tested in the SENTRY Program,
are shown in Table 1. The susceptibility test methods
were discriminated by the participating medical center
for only 4,159 (40.5%) isolates. The most frequent
method used by the participating laboratories was disk
diffusion (23.4%), followed by the automated Vitek
system (9.2%).
Overall, the rate of categorical agreement was
88.5%. The combination B. cepacia–imipenem
showed the lowest categorical agreement (51.7%),
followed by Klebsiella spp.– ceftriaxone (77.9%),
Klebsiella spp.– ceftazidime (79.4%), and CoNS–
oxacillin (79.6%). The other antimicrobial agent –
organism combinations showed > 90% categorical
agreements (Table 2).
The “very major” errors ranged from 0.0% for E.
coli-ceftriaxone to 20.5% for CoNS-oxacillin; with the
exception of the former combination, none of the
antimicrobial agent-organism combinations presented
an acceptable rate of very major errors. When “major”
errors were analyzed, only 60% of the antimicrobial
agent-organism combinations showed acceptable rates
(< 5.0%).
To evaluate the susceptibility test systems, it was
necessary to determine the power of discrimination
of the various antimicrobial susceptibility test
methodologies used by the participating centers,
followed by the respective susceptibility test results.
Only 3,268 isolates had the susceptibility tests systems
data accompanied by the corresponding susceptibility
tests results. Etest, PASCO, agar dilution and
MicroScan showed the highest categorical
agreement (92.6%, 91.6%, 91.3% and 90.1%,
respectively). The percentage of “very major” error
varied from 5.2% for agar dilution to 25.0% for the
Etest (Table 3).
The categorical agreement varied from 83.6% for
medical center 092 to 100.0% for medical center 042.
Except for medical center 042, none of the centers
had acceptable “very major” error rates (Table 4).
Discussion
Similar to what occurs in Latin American routine
microbiology laboratories, the Kirby-Bauer disk
diffusion test was the most common (23.5%)
antimicrobial susceptibility test used by the Latin
American medical centers participating in this study.
The predominance of disk diffusion is probably due to
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Table 1. Antimicrobial susceptibility testing methods used and the respective number of isolates tested by each of the participating medical
centers in the SENTRY Antimicrobial Surveillance Program
Medical No. of isolates tested by each methodology Total Not availableb Total
Center
Agar dilution Disk diffusion Etesta MicroScana Pascoa Viteka
039 151 203 25 379 671 1,050
040 162 49 211 898 1,109
041 17 239 256 248 504
042 01 01 976 977
043 124 39 81 244 887 1,131
044 51 288 339 552 891
045 05 96 142 243 314 557
046 112 443 555 574 1,129
047 87 40 127 58 185
048 1,416 1416 21 1,437
049 71 71 399 470
056 15 15 21 36
057 242 242 427 669
092 60 60 72 132
Total 336 2,405 40 384 49 945 4,159 6,118 10,277
(3.3%) (23.4%) (0.4%) (3.7%) (0.5%) (9.2%) (40.5%) (59.5%)
a – Etest (AB Biodisk, Solna, Sweden); MicroScan (Dade Behring, West Sacramento, California); Vitek (bioMérieux, Hazelwood); PASCO (Becton-Dickinson,
Wheatridge, Colombia). b – Methodology not reported.
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Table 2. Accuracy data of antimicrobial agent-organism combinations
Table 3. Evaluation of the antimicrobial susceptibility test systems used by the Latin American medical centers
Antimicrobial Resistance Patterns in Latin America Laboratories
Microorganism Antimicrobial Number tested % Categorical % Error (errors/available results)
agents agreementa
Very majorb Majorc
B. cepacia Imipenem 58 51.7 21.1 (4/19) 25.0 (7/28)
CoNSd Oxacillin 986 79.6 20.5 (146/710) 17.7 (49/276)
Klebsiella spp. Ceftriaxone 249 77.9 13.2 (7/53) 11.0 (19/173)
Ceftazidime 776 79.4 5.8 (17/295) 20.4 (89/436)
P. aeruginosa Imipenem 1274 86.9 12.8 (30/233) 3.8 (37/955)
Escherichia coli Ceftriaxone 441 93.6 0.0 (0/10) 3.1 (13/415)
Ceftazidime 1065 91.4 19.7 (13/66) 5.0 (49/974)
S. malthophilia Imipenem 82 91.4 8.6 (7/81) 0.0 (0/1)
Acinetobacter spp. Imipenem 545 92.1 12.1 (8/66) 4.4 (21/471)
S. aureus Oxacillin 2278 95.1 7.7 (59/764) 3.4 (52/1514)
Total 7754 88.5 12.7 (291/2297) 6.4 (336/5243)
a – Number of tests with category agreement divided by the number of organisms tested.
b – % very major error: number of false-susceptible strains divided by the number of true resistant strains.
c – % major error: number of false-resistant strains divided by the number of true susceptible strains.
d – Coagulase-negative Staphylococcus.
Methodologya Number of % Categoricalb % Error (errors/available results)
isolates tested agreement
Very majorc Majord
Etest 27 92.6 25.0 (1/4) 4.3 (1/23)
PASCO 36 91.6 0.0 (0/2) 3.1 (1/32)
Agar dilution 276 91.3 5.2 (5/96) 7.4 (13/176)
MicroScan 314 90.1 12.3 (7/57) 7.1 (18/252)
Vitek 682 89.7 11.0 (18/163) 6.1 (31/502)
Disk-diffusion 1933 87.3 11.5 (83/720) 5.9 (68/1147)
a – Etest (AB Biodisk, Solna, Sweden); MicroScan (Dade Behring, West Sacramento, California); Vitek (bioMérieux,
      Hazelwood); PASCO (Becton-Dickinson, Wheatridge, Colombia).
b – Number of tests with category agreement divided by the number of organisms tested.
c – % very major error: number of false-susceptible strains divided by the number of true resistant strains.
d – % major error: number of false-resistant strains divided by the number of true susceptible strains.
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Table 4. Evaluation of susceptibility test accuracy according in each of the medical centers
low cost, flexibility and demonstrated accuracy.
However, the use of semi-quantitative automated
systems has recently been increasing [11].
Detection of methicillin-resistant coagulase-negative
Staphylococcus spp. isolates by phenotypic methods
is a challenge for most clinical microbiology laboratories.
The NCCLS recently proposed that the most sensitive,
practical method for the detection of this type of
resistance was either the broth microdilution
determination of the oxacillin MIC or the oxacillin disk
diffusion test, with breakpoints specific for coagulase-
negative Staphylococcus spp. [12]. However, the
participating laboratories showed a high rate of errors
for the CoNS–oxacillin combination (20.5%). This
result leads us to suggest that the participating centers
may not be applying the latest NCCLS document
criteria for interpretation.
High rates of false-susceptibility results (“very
major” errors) were encountered among Klebsiella
spp. strains when the pathogen was tested against
ceftriaxone (13.2%) and ceftazidime (5.8%). The E.
coli–ceftazidime combination also showed high rates
of “very major” errors (19.7%). The high rates of errors
described above may be explained by the high
prevalence of extended-spectrum β-lactamase (ESBL)
producing strains among these species throughout Latin
America. Because of differences in drug substrate
affinities of some ESBLs, and the resulting inoculum
effects with standard susceptibility tests, ESBL
producing isolates may give rise to inconsistent results
when tested by any methodology [13].
Acinetobacter spp. and P. aeruginosa are highly
prevalent pathogens in Latin America. In addition, the
nosocomial prevalence of S. maltophilia is increasing.
When these pathogens were tested against imipenem
we expected high rates of false-resistant results (major
errors), since the instability of imipenem could cause
these types of errors. However, among these species,
the major errors were within acceptable rate levels
(<5.0%). On the other hand, high frequencies of false-
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Medical center Number of % Categorical %Error (errors/available results)
isolates tested agreementa
Very majorb Majorc
039 867 90.9 5.1 (13/256) 6.3 (37/587)
040 964 86.1 8.4 (28/334) 10.7 (63/590)
041 419 89.5 9.3 (10/107) 4.7 (14/296)
042 17 100.0 0.0 (0/11) 0.0 (0/6)
043 724 86.6 22.3 (68/305) 5.3 (22/413)
044 903 90.0 13.6 (17/125) 5.7 (43/752)
045 409 88.5 35.4 (23/65) 3.6 (12/332)
046 924 92.4 12.2 (25/205) 4.1 (29/705)
047 152 94.7 13.0 (3/23) 1.6 (2/125)
048 1189 86.0 13.6 (71/522) 7.2 (46/634)
049 409 82.4 6.0 (7/116) 16.3 (45/276)
056 38 92.1 15.4 (2/13) 4.0 (1/25)
057 643 90.5 11.8 (22/187) 3.7 16/431)
092 49 83.6 10.0 (2/20) 16.6 (4/24)
a – Number of tests with category agreement divided by the number of organisms tested.
b – % very major error: number of false-susceptible strains divided by the number of true resistant strains.
c – % major error: number of false-resistant strains divided by the number of true susceptible strains.
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susceptibility results (very major errors) from 8.6% to
12.8% were observed among these non-fermenting
pathogens.
Burholderia cepacia strains showed the lowest
categorical agreement (51.7%) and the highest rates
of very major (21.1%) and major errors (25.0%).
Additionally, although S. malthophilia is intrinsically
resistant to imipenem, several of the participating
laboratories reported seven isolates as susceptible.
These poor results are probably due to the lack of
standardized susceptibility testing methods for both S.
malthophilia and B. cepacia.
Stenotrophomonas maltophilia and B. cepacia
isolates present problems since the interpretative
category results of disk diffusion and automated systems
may not agree with susceptibility categories based on
reference MIC determination. Pankuch et al. [14] also
found a poor correlation among five susceptibility
testing methods evaluated against eight β-lactams
(including β-lactam-β-lactamase inhibitor
combinations) and ciprofloxacin antimicrobial agents
against S. maltophilia.
The NCCLS currently recommends that only
reference quantitative testing methods should be used
on S. maltophilia [8]. Unfortunately, these methods
are labor-intensive, and thus, difficult to incorporate
into routine laboratory procedures. Susceptibility testing
of S. maltophilia by disk diffusion or by semi-
automated methods, such as Vitek (bioMerieux Inc.,
Hazelwood, MO.) or MicroScan (Baxter Health Care
Corp., Sacramento, CA) is unreliable and therefore
not recommended [15].
In the evaluation of the susceptibility test methods/
systems, “very major” error rates varied from 5.2% to
25.0% depending on the methodology utilized and the
species tested (Table 3). The limited number of truely
resistant isolates may have influenced the major error
rates of some methodologies. Only 57 and 4 true
resistant isolates were tested by MicroScanand
Etest. Thus, a low number of false susceptible reports
could result in unacceptable rates of very major errors.
In the S. aureus–oxacillin combination, among 7
truly resistant strains, 2 isolates (29%) were reported
as susceptible by MicroScan (data not shown).
Automated systems have excellent specificity but often
do not have sensitivity in detecting methicillin-resistant
staphylococci, probably due to the reduced incubation
period (24 hours) and lack of 2% NaCl [16]. A similar
problem was observed when using the disk diffusion
test method, where 49 out of 83 “very major” errors
were detected in the CoNS–oxacillin combination.
Additionally, among the Vitek system results the
highest rate of “very major” errors was detected for
the P. aeruginosa–imipenem combination (8/18, 44%).
This result was unexpected since false-resistant errors
would be prominent, as described above.
Except for the “major error” rates described for
medical centers 043 and 045, categorical agreement
and “very major” errors occurred at similar rates in all
participating medical centers. The high “very major”
rates observed in medical centers 043 and 045 were
caused by the CoNS–oxacillin combination. These
results could also be explained by the use of the
previously used oxacillin breakpoint [9].
Generally speaking, we found low rates of
categorical agreement, and high rates of “very major”
and “major” errors. The fact that only problematic
antimicrobial agents-organism combinations were
selected for evaluation may have resulted in an
overestimate of the error rates. In addition, clinical
laboratories should not rely on a single susceptibility
testing methodology to detect emerging resistant
organisms [17].
It is important to recognize that subtle resistance
mechanisms, especially among fastidious and slow-
growing organisms, may not be detected by any
methodology with the same level of reproducibility and
accuracy that can be expected for most other organism-
antibiotic combinations. Additionally, it is possible to
perform a test correctly but report inaccurate results,
particularly if obsolete guidelines or criteria are used.
The correct interpretation and reporting of the
antimicrobial susceptibility test results is as important
as the ability to detect the resistance mechanism
accurately.
External quality assurance data obtained by
surveillance programs such as the SENTRY
Antimicrobial Surveillance Program are not only helpful
Antimicrobial Resistance Patterns in Latin America Laboratories
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for detecting the emergence of patterns of antimicrobial
resistance, but also for monitoring the performance of
the participating microbiology laboratories.
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